Navigation Links
Covance Reports Fourth Quarter Pro Forma Net Revenue Of $561 Million, Pro Forma EPS Of $0.73 And Adjusted Net Orders Of $769 Million
Date:1/24/2013

"Late-Stage Development fourth quarter revenues grew 15.7% year-on-year to $345 million. This increase was led by 22% growth in clinical development and 16% growth in central laboratories, which more than offset a decline in our market access services. Late-Stage Development pro forma operating margins increased 130 basis points both year-on-year and sequentially to 21.3%.  In Early Development, pro forma revenue of $216 million and pro forma operating margin of 12.0% declined modestly from the third quarter level on lower demand for discovery support services.

"Looking ahead to 2013, for the full year, we are forecasting mid- to high-single digit year-on-year revenue growth and pro forma diluted earnings per share, which exclude costs from ongoing restructuring activities, in the range of $2.85 to $3.15 (assuming foreign exchange rates remain at year-end 2012 levels).  In the first quarter of 2013, we expect revenue to be up slightly from the fourth quarter level and pro forma earnings per share to be in the range of $0.71 to $0.73 as we forecast an increase in Late-Stage Development net revenues and earnings to be off-set by seasonally-lower first quarter Early Development results." 

Consolidated Results($ in millions except EPS)4Q124Q11ChangeFY12FY11ChangeTotal Revenues

$609.1

$582.4$2,365.7

$2,236.4Less: Reimbursable Out-of-Pockets 

$46.9

$49.9$185.1

$140.5Net Revenues

$562.2

$532.5

5.6%

$2,180.6

$2,095.9

4.0%Operating Income

$43.1

$39.0

10.6%

$115.9

$180.6

(35.8%)Operating Margin

7.7%

7.3%5.3%

8.6%Net Income

$33.9

$21.1

60.3%

$94.7

$132.2

(28.3%)Diluted Earnings per Share

$0.61

$0.35

77.5%

$1.68

$2.16

(22.2%)Revenue from
'/>"/>

SOURCE Covance Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Covance To Present At The William Blair 32nd Annual Growth Stock Conference
2. Covance Reports Second Quarter Pro Forma Net Revenue Of $538 Million, Pro Forma EPS Of $0.65 And Adjusted Net Orders Of $701 Million
3. Covance to Present at the Morgan Stanley Global Healthcare Conference
4. Covance Reports Third Quarter Pro Forma Net Revenue Of $542 Million, Pro Forma EPS Of $0.72 And Adjusted Net Orders Of $701 Million
5. Covance To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
6. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
7. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
8. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
9. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
10. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
11. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... August 28, 2015 The report "Eubiotics Market by ... Poultry, Ruminant, and Aquaculture), & by Region ( North ... Asia-Pacific , and Rest of the World) - Global ... market for Eubiotics was valued at USD 4.62 Billion in ... 2020, at a CAGR of 7.4% from 2015 to 2020. ...
(Date:8/28/2015)... , August 28, 2015 ... seamlessly connects people, technologies and care protoc ols ... outcomes and the cost of healthcare delivery   ... its presence at  ESC Congress 2015 , where the company ... , EchoNavigator and IntelliSpace Cardiovascular, that connect people and technology ...
(Date:8/27/2015)...  The Academy of Managed Care Pharmacy (AMCP) ... draft guidance and proposed rule that calls for ... a nonproprietary name with an FDA-designated suffix. For ... from the FDA on the naming issue and ... the agency to use the same nonproprietary names ...
Breaking Medicine Technology:Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2
... Vical Incorporated (Nasdaq:,VICL) announced today that results ... trials, using a plasmid DNA (pDNA) vaccine developed ... Vical, reinforced previously,reported Phase 1 conclusions that a ... well-tolerated, and was effective in inducing,T-cell immune responses ...
... Single, Higher, More Concentrated Dose of ... ... Inc.,(Nasdaq: NUVO ) today announced enrollment of the first patient ... trial evaluating lead product candidate,alfimeprase, for the treatment of central venous ...
Cached Medicine Technology:Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results 2Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results 3Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion 2Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion 3Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion 4
(Date:8/30/2015)... ... August 30, 2015 , ... SonaCare ... for the treatment of prostate cancer, has announced the roll-out of its newest ... treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology currently in use ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, 2015, ... Research Foundation (Meso Foundation) will present an educational program titled “Asbestos and Your ... lasts through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, 16 ...
(Date:8/29/2015)... ... , ... Dr. Tim Novelli, DC., Founder and President of the Patriot Project, ... the chiropractic field in the military. All too often VA hospitals treat patients with ... available to the VA program over a decade ago, the reality is that only ...
(Date:8/29/2015)... Calgary, AB (PRWEB) , ... August 29, 2015 ... ... congestive heart failure, angina, chronic obstructive pulmonary disease (including emphysema), or asthma, are ... conditions such as angina, previous heart attack, heart failure or heart-rhythm problems (arrhythmia ...
(Date:8/28/2015)... Tempe, AZ (PRWEB) , ... August 29, 2015 , ... ... to reinvent higher learning and the student experience as part of the EDUCAUSE - ... Melinda Gates Foundation . , This is the third Breakthrough Models Incubator ...
Breaking Medicine News(10 mins):Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4
... PRINCETON, N.J., March 9 NJHA Corporate Services ... Morganville, N.J., to offer training and consulting services ... the healthcare environment. The deal comes on the ... Facilities Act, which directs healthcare facilities to establish ...
... Pa., March 9 Genaera Corporation (Nasdaq: ... Rule 4350(b)(1)(B), that the audit report included in the ... the fiscal year ended December 31, 2008 contained an ... firm, KPMG LLP, which included a "going concern" explanatory ...
... action, which is expected to kick-start efforts to unlock ... Separating science from politics with his signature, President Barack ... research on Monday. , During a late morning press ... limits on such research that were first imposed by ...
... Name Youth as ,First Responders, , in the ... order to address the growing childhood obesity epidemic, ... supporting youth-led projects that focus on healthy lifestyles ... two national partners also published an educational guide ...
... against the disease, study finds , , MONDAY, March 9 (HealthDay ... that puts them at higher risk of breast cancer tend ... Several type of risk management strategies are available to women ... is known to elevate a woman,s risk of breast cancer. ...
... Medicare Advantage Special Needs Plans, Tips for Healthy ... A series of free seminars designed to help ... a healthy lifestyle and learn about Medicare Advantage ... will be offered during March at various locations ...
Cached Medicine News:Health News:NJHA, McNamara and Associates Inc. Team Up to Provide Strategies for Controlling Workplace Violence 2Health News:Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph 2Health News:Obama Lifts Ban on Stem Cell Research 2Health News:Obama Lifts Ban on Stem Cell Research 3Health News:Obama Lifts Ban on Stem Cell Research 4Health News:'HEROES' Grants, Education Guide Support Youth Leaders Addressing Childhood Obesity Epidemic 2Health News:'HEROES' Grants, Education Guide Support Youth Leaders Addressing Childhood Obesity Epidemic 3Health News:Women With Breast Cancer Gene Favor Preventive Mastectomy 2Health News:Free Seminars Offered to South Carolina Seniors with Diabetes and Other Chronic Illnesses 2
Simplicity and multi-directional retraction for a broad range of abdominal procedures...
... genuine BOOKWALTER™ Retractor System represents the ... design available. Its wide array of ... with a versatile system for multi-directional ... BOOKWALTER™ Kits are available for specific ...
Rainbow technology combines the latest in system theory, adaptive signal processing and a revolutionary sensor that employs eight wavelengths of light to collect and analyze an extraordinarily rich s...
... Another breakthrough in real-time PCR analysis ... mutation analysis. ,The LightCycler 480 System ... and will meet the needs of ... in genomics research including array validation, ...
Medicine Products: